Thrombocytopenia associated with chronic liver disease

被引:465
作者
Afdhal, Nezam [1 ]
McHutchison, John [2 ]
Brown, Robert [3 ]
Jacobson, Ira [4 ]
Manns, Michael [5 ]
Poordad, Fred [6 ]
Weksler, Babette [4 ]
Esteban, Rafael [7 ]
机构
[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Columbia Univ, Med Ctr, New York, NY USA
[4] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[5] Hannover Med Sch, Hannover, Germany
[6] Ctr Liver Dis & Transplantat, Cedars Sinai Med Ctr, Los Angeles, CA USA
[7] Univ Autonoma Barcelona, Hosp Univ Vall Hebron, E-08193 Barcelona, Spain
关键词
chronic liver disease; cirrhosis; cytopenia; platelets; thrombocytopenia; thrombopoietin; platelet transfusion;
D O I
10.1016/j.jhep.2008.03.009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Thrombocytopenia (platelet count <.150,000/mu L) is a common complication in patients with chronic liver disease (CLD) that has been observed in up to 76% of patients. Moderate thrombocytopenia (platelet count, 50,000/mu L-75,000/mu L) occurs in approximately 13% of patients with cirrhosis. Multiple factors can contribute to the development of thrombocytopenia, including splenic platelet sequestration, bone marrow suppression by chronic hepatitis C infection, and antiviral treatment with interferon-based therapy. Reductions in the level or activity of the hematopoietic growth factor thrombopoietin (TPO) may also play a role. Thrombocytopenia can impact routine care of patients with CLD, potentially postponing or interfering with diagnostic and therapeutic procedures including liver biopsy, antiviral therapy, and medically indicated or elective surgery. Therapeutic options to safely and effectively raise platelet levels could have a significant effect on care of these patients. Several promising novel agents that stimulate TPO and increase platelet levels, such as the oral platelet growth factor eltrombopag, are currently in development for the prevention and/or treatment of thrombocytopenia. The ability to increase platelet levels could significantly reduce the need for platelet transfusions and facilitate the use of interferon-based antiviral therapy and other medically indicated treatments in patients with liver disease. (c) 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1000 / 1007
页数:8
相关论文
共 60 条
[21]   PURIFICATION AND BIOLOGIC CHARACTERIZATION OF PLASMA-DERIVED MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR [J].
HUNT, P ;
LI, YS ;
NICHOL, JL ;
HOKOM, MM ;
BOGENBERGER, JM ;
SWIFT, SE ;
SKRINE, JD ;
HORNKOHL, AC ;
LU, H ;
CLOGSTON, C ;
MEREWETHER, LA ;
JOHNSON, MJ ;
PARKER, V ;
KNUDTEN, A ;
FARESE, A ;
HSU, RY ;
GARCIA, A ;
STEAD, R ;
BOSSELMAN, RA ;
BARTLEY, TD .
BLOOD, 1995, 86 (02) :540-547
[22]  
INABNET WB, 1995, AM SURGEON, V61, P603
[23]   Induction of megakaryocytopoiesis and thrombocytopoiesis by JTZ-132, a novel small molecule with thrombopoietin mimetic activities [J].
Inagaki, K ;
Oda, T ;
Naka, Y ;
Shinkai, H ;
Komatsu, N ;
Iwamura, H .
BLOOD, 2004, 104 (01) :58-64
[24]   Does transjugular intrahepatic portosystemic shunt (TIPS) resolve thrombocytopenia associated with cirrhosis? [J].
Jabbour, N ;
Zajko, A ;
Orons, P ;
Irish, W ;
Fung, JJ ;
Selby, RR .
DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (11) :2459-2462
[25]   Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist [J].
Jenkins, Julian M. ;
Williams, Daphne ;
Deng, Yanli ;
Uhl, Joanne ;
Kitchen, Valerie ;
Collins, David ;
Erickson-Miller, Connie L. .
BLOOD, 2007, 109 (11) :4739-4741
[26]   Thrombopoietin [J].
Kaushansky, K .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (11) :746-754
[27]   Recombinant human thrombopoietin: basic biology and evaluation of clinical studies [J].
Kuter, DJ ;
Begley, CG .
BLOOD, 2002, 100 (10) :3457-3469
[28]   Thrombocytopenia caused by the development of antibodies to thrombopoietin [J].
Li, JZ ;
Yang, C ;
Xia, YP ;
Bertino, A ;
Glaspy, J ;
Roberts, M ;
Kuter, DJ .
BLOOD, 2001, 98 (12) :3241-3248
[29]   Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity [J].
Lisman, T ;
Bongers, TN ;
Adelmeijer, J ;
Janssen, HLA ;
de Maat, MPM ;
de Groot, PG ;
Leebeek, FWG .
HEPATOLOGY, 2006, 44 (01) :53-61
[30]   Prediction of esophageal varices in patients with cirrhosis [J].
Madhotra, R ;
Mulcahy, HE ;
Willner, I ;
Reuben, A .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2002, 34 (01) :81-85